498 related articles for article (PubMed ID: 34493414)
1. Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial.
Kwan EM; Spain L; Anton A; Gan CL; Garrett L; Chang D; Liow E; Bennett C; Zheng T; Yu J; Dai C; Du P; Jia S; Fettke H; Abou-Seif C; Kothari G; Shaw M; Parente P; Pezaro C; Tran B; Siva S; Azad AA
Eur Urol; 2022 Mar; 81(3):253-262. PubMed ID: 34493414
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.
Yu EY; Kolinsky MP; Berry WR; Retz M; Mourey L; Piulats JM; Appleman LJ; Romano E; Gravis G; Gurney H; Bögemann M; Emmenegger U; Joshua AM; Linch M; Sridhar S; Conter HJ; Laguerre B; Massard C; Li XT; Schloss C; Poehlein CH; de Bono JS
Eur Urol; 2022 Jul; 82(1):22-30. PubMed ID: 35397952
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.
Yu EY; Piulats JM; Gravis G; Fong PCC; Todenhöfer T; Laguerre B; Arranz JA; Oudard S; Massard C; Heinzelbecker J; Nordquist LT; Carles J; Kolinsky MP; Augustin M; Gurney H; Tafreshi A; Li XT; Qiu P; Poehlein CH; Schloss C; de Bono JS
Eur Urol; 2023 Jan; 83(1):15-26. PubMed ID: 36055895
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial.
Siva S; Bressel M; Wood ST; Shaw MG; Loi S; Sandhu SK; Tran B; A Azad A; Lewin JH; Cuff KE; Liu HY; Moon D; Goad J; Wong LM; LimJoon M; Mooi J; Chander S; Murphy DG; Lawrentschuk N; Pryor D
Eur Urol; 2022 Apr; 81(4):364-372. PubMed ID: 34953600
[TBL] [Abstract][Full Text] [Related]
5. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
Yap TA; Bardia A; Dvorkin M; Galsky MD; Beck JT; Wise DR; Karyakin O; Rubovszky G; Kislov N; Rohrberg K; Joy AA; Telli ML; Schram AM; Conte U; Chappey C; Stewart R; Stypinski D; Michelon E; Cesari R; Konstantinopoulos PA
JAMA Oncol; 2023 Jan; 9(1):40-50. PubMed ID: 36394849
[TBL] [Abstract][Full Text] [Related]
6. A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.
Fong L; Morris MJ; Sartor O; Higano CS; Pagliaro L; Alva A; Appleman LJ; Tan W; Vaishampayan U; Porcu R; Tayama D; Kadel EE; Yuen KC; Datye A; Armstrong AJ; Petrylak DP
Clin Cancer Res; 2021 Sep; 27(17):4746-4756. PubMed ID: 34108181
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study.
Yu EY; Berry WR; Gurney H; Retz M; Conter HJ; Laguerre B; Fong PCC; Ferrario C; Todenhöfer T; Gravis G; Piulats JM; Emmenegger U; Shore ND; Romano E; Mourey L; Li XT; Poehlein CH; Schloss C; Appleman LJ; de Bono JS
Eur Urol Oncol; 2024 Jun; 7(3):509-518. PubMed ID: 37940446
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide.
La Vecchia M; Fazio I; Borsellino N; Lo Casto A; Galanti D
Tumori; 2023 Aug; 109(4):413-417. PubMed ID: 36358013
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study.
Rodriguez-Vida A; Maroto P; Font A; Martin C; Mellado B; Corbera A; Orrillo M; Reig O; Querol R; Rios-Hoyo A; Cano L; Alonso J; Martinez G; Galtes S; Taus A; Martinez-Garcia M; Juanpere N; Juan O; Bellmunt J
Br J Cancer; 2023 Jan; 128(1):21-29. PubMed ID: 36289372
[TBL] [Abstract][Full Text] [Related]
10. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment.
Subudhi SK; Siddiqui BA; Aparicio AM; Yadav SS; Basu S; Chen H; Jindal S; Tidwell RSS; Varma A; Logothetis CJ; Allison JP; Corn PG; Sharma P
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663638
[TBL] [Abstract][Full Text] [Related]
11. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F
Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231
[TBL] [Abstract][Full Text] [Related]
12. [Combining avelumab and stereotactic ablative body radiotherapy in metastatic castration-resistant prostate cancer : Efficacy and safety-phase II ICE-PAC].
Krafft UA
Urologe A; 2022 Mar; 61(3):301-303. PubMed ID: 34918182
[No Abstract] [Full Text] [Related]
13. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.
Siva S; Bressel M; Murphy DG; Shaw M; Chander S; Violet J; Tai KH; Udovicich C; Lim A; Selbie L; Hofman MS; Kron T; Moon D; Goad J; Lawrentschuk N; Foroudi F
Eur Urol; 2018 Oct; 74(4):455-462. PubMed ID: 30227924
[TBL] [Abstract][Full Text] [Related]
14. ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study.
Stein MN; Fong L; Tutrone R; Mega A; Lam ET; Parsi M; Vangala S; Gutierrez AA; Haas NB
Oncologist; 2022 Jun; 27(6):453-461. PubMed ID: 35373299
[TBL] [Abstract][Full Text] [Related]
15. First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC).
Autio KA; Higano CS; Nordquist L; Appleman LJ; Zhang T; Zhu XH; Babiker H; Vogelzang NJ; Prasad SM; Schweizer MT; Madan RA; Billotte S; Cavazos N; Bogg O; Li R; Chan K; Cho H; Kaneda M; Wang IM; Zheng J; Tang SY; Hollingsworth R; Kern KA; Petrylak DP
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36948505
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy.
Ingrosso G; Detti B; Fodor A; Caini S; Borghesi S; Triggiani L; Trippa F; Russo D; Bruni A; Francolini G; Lancia A; Marinelli L; Di Muzio N; Livi L; Magrini SM; Maranzano E; Musio D; Aristei C; Valeriani M
Clin Transl Oncol; 2021 Aug; 23(8):1577-1584. PubMed ID: 33495981
[TBL] [Abstract][Full Text] [Related]
17. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
[TBL] [Abstract][Full Text] [Related]
18. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
Graff JN; Beer TM; Alumkal JJ; Slottke RE; Redmond WL; Thomas GV; Thompson RF; Wood MA; Koguchi Y; Chen Y; Latour E; Bergan RC; Drake CG; Moran AE
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616555
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer.
Hannan R; Christensen M; Christie A; Garant A; Pedrosa I; Robles L; Mannala S; Wang C; Hammers H; Arafat W; Courtney K; Bowman IA; Sher D; Ahn C; Cole S; Choy H; Timmerman R; Brugarolas J
Eur Urol Oncol; 2022 Dec; 5(6):695-703. PubMed ID: 35985982
[TBL] [Abstract][Full Text] [Related]
20. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
